S100A9 and benign prostatic hyperplasia: For example, in a study that proposed that serum S100A9 would serve as a useful marker to discriminate between prostate cancer and benign prostatic hyperplasia, the serum S100A9 concentration measured by ELISA was about 2–14 ng/mL in cancer patients [22].